Tagrisso
Tagrisso Approved for Some With Locally Advanced, Unresectable Stage III NSCLC Following Chemoradiation
The FDA has approved osimertinib (Tagrisso, AstraZeneca) for adult patients with locally advanced, unresectable ...
SEPTEMBER 25, 2024
For Patients With EGFR-Mutated Lung Cancer, Osimertinib Trial Might Change Guidelines
In patients with unresectable epidermal growth factor receptor−mutated (EGFRm), stage III non-small cell lung ...
JULY 10, 2024
Tagrisso Approved With Chemotherapy for EGFR-mutated NSCLC
The FDA approved osimertinib (Tagrisso, AstraZeneca Pharmaceuticals LP) with platinum-based chemotherapy for ...
FEBRUARY 16, 2024
Tagrisso Approved as First Adjuvant Treatment of EGFR-Mutated NSCLC
The FDA approved osimertinib (Tagrisso, AstraZeneca) for adjuvant therapy after tumor resection in adults with ...
JANUARY 3, 2021
Load more